0 CHECKOUT

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015

  • ID: 3259627
  • April 2015
  • 102 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Centrose Llc
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Gilead Sciences, Inc.
  • Incuron, LLC
  • MORE

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015

Summary

This, ‘Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2015’, provides an overview of the Pancreatic Ductal Adenocarcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pancreatic Ductal Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Ductal Adenocarcinoma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Centrose Llc
  • Clovis Oncology, Inc.
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Gilead Sciences, Inc.
  • Incuron, LLC
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Pancreatic Ductal Adenocarcinoma Overview
Therapeutics Development
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Overview
Pipeline Products for Pancreatic Ductal Adenocarcinoma - Comparative Analysis
Pancreatic Ductal Adenocarcinoma - Therapeutics under Development by Companies
Pancreatic Ductal Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes
Pancreatic Ductal Adenocarcinoma - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Pancreatic Ductal Adenocarcinoma - Products under Development by Companies
Pancreatic Ductal Adenocarcinoma - Products under Investigation by Universities/Institutes
Pancreatic Ductal Adenocarcinoma - Companies Involved in Therapeutics Development
Centrose Llc
Clovis Oncology, Inc.
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Gilead Sciences, Inc.
Incuron, LLC
InvivoGen Therapeutics
Medisyn Technologies, Inc.
Merck & Co., Inc.
Nerviano Medical Sciences S.r.l.
OncoMed Pharmaceuticals, Inc.
Pfizer Inc.
SillaJen Co. Ltd.
Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CBL-0137 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CYL-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
demcizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EDC-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FG-3019 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hu-5F9G4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ipafricept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JX-929 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-0752 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MK-8628 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
momelotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRK-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MT-477 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NMSP-715 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-03084014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PSL-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-7787 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rucaparib phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SiG12D-LODER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit Wnt Signal and eIF5A for Pancreatic Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Modulate GLT-1 for Pancreatic Ductal Adenocarcinoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vantictumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pancreatic Ductal Adenocarcinoma - Recent Pipeline Updates
Pancreatic Ductal Adenocarcinoma - Dormant Projects
Pancreatic Ductal Adenocarcinoma - Discontinued Products
Pancreatic Ductal Adenocarcinoma - Product Development Milestones
Featured News & Press Releases
Jun 25, 2013: Cleveland BioLabs And Incuron Announce Poster Presentation At ESMO 15th World Congress On Gastrointestinal Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2015
Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Centrose Llc, H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Clovis Oncology, Inc., H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by FibroGen, Inc., H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Gilead Sciences, Inc., H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Incuron, LLC, H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by InvivoGen Therapeutics, H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Merck & Co., Inc., H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Nerviano Medical Sciences S.r.l., H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by Pfizer Inc., H1 2015
Pancreatic Ductal Adenocarcinoma - Pipeline by SillaJen Co. Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Pancreatic Ductal Adenocarcinoma Therapeutics - Recent Pipeline Updates, H1 2015
Pancreatic Ductal Adenocarcinoma - Dormant Projects, H1 2015
Pancreatic Ductal Adenocarcinoma - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Pancreatic Ductal Adenocarcinoma, H1 2015
Number of Products under Development for Pancreatic Ductal Adenocarcinoma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Centrose Llc
Clovis Oncology, Inc.
F. Hoffmann-La Roche Ltd.
FibroGen, Inc.
Gilead Sciences, Inc.
Incuron, LLC
InvivoGen Therapeutics
Medisyn Technologies, Inc.
Merck & Co., Inc.
Nerviano Medical Sciences S.r.l.
OncoMed Pharmaceuticals, Inc.
Pfizer Inc.
SillaJen Co. Ltd.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Photocure ASA
  • Roche Diagnostics Ltd.
  • Abbott Laboratories Ltd.
  • Pfizer Inc.
  • Novartis AG
  • Becton, Dickinson and Company (BD)